慢性危重症的发生决定外科ICU脓毒症早期存活者的躯体功能、生活质量与长期生存
本研究为单机构前瞻性纵向观察性队列,纳入2个外科/创伤ICU中脓毒症发病后存活≥14天的成人危重症患者173例,比较发生慢性危重症(ICU停留≥14天且持续器官功能障碍)者63例(36%)与快速恢复者110例(64%)的12个月结局。两组基线躯体功能与健康相关生活质量无差异;慢性危重症组无住院天数显著更少(196±148 vs 321±65,p<0.0001),12个月生存率显著更低(54% vs 92%,p<0.0001)。3、6个月随访时慢性危重症组躯体功能与生活质量显著更差,至12个月时所有测量指标均显著更差。作者结论认为需进一步理解驱动慢性危重症发生与持续的机制以改善脓毒症后长期结局。
要点
- 外科/创伤ICU脓毒症存活≥14天的成人中,36%(63/173)发展为慢性危重症(ICU停留≥14天且持续器官功能障碍)。
- 慢性危重症组12个月生存率54% vs 快速恢复组92%(p<0.0001),无住院天数196±148 vs 321±65(p<0.0001)。
- 两组基线躯体功能与健康相关生活质量无差异,提示长期结局差异由慢性危重症的发生所决定。
- 3个月与6个月随访时慢性危重症组躯体功能(3个月:短物理性能 battery、Zubrod、握力;6个月:短物理性能 battery、Zubrod)与生活质量(3、6个月:EuroQol-5D-3L)显著更差。
- 至12个月随访,慢性危重症组在所有测量指标上的躯体功能与健康相关生活质量均显著更差。
适用人群与场景
- 纳入:2个外科/创伤ICU中脓毒症发病后存活≥14天的成人危重症患者。
- 场景:学术三级医疗中心及1级创伤中心的外科/创伤ICU。
诊断标准与关键阈值
- 慢性危重症定义:ICU停留≥14天且持续器官功能障碍。
- 快速恢复:未达到慢性危重症定义者。
研究设计与关键结果
- 研究设计:单机构前瞻性纵向观察性队列,评估12个月结局。
- 样本量:173例脓毒症患者,其中慢性危重症63例(36%),快速恢复110例(64%)。
- 主要结局:慢性危重症组无住院天数196±148 vs 快速恢复组321±65(p<0.0001);12个月生存率54% vs 92%(p<0.0001)。
- 基线:两组基线躯体功能与健康相关生活质量无差异。
- 3个月随访:慢性危重症组短物理性能 battery、Zubrod、握力及EuroQol-5D-3L显著更差。
- 6个月随访:慢性危重症组短物理性能 battery、Zubrod及EuroQol-5D-3L显著更差。
- 12个月随访:慢性危重症组所有躯体功能与健康相关生活质量测量指标均显著更差。
证据类型、等级与局限
- 证据类型:单机构前瞻性纵向观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于外科/创伤ICU脓毒症发病后存活≥14天的患者,应认识到约36%将发展为慢性危重症,其12个月生存率仅54%、无住院天数显著减少,躯体功能与生活质量长期更差。
- 作者认为,需进一步理解驱动慢性危重症发生与持续的机制,以改善脓毒症后长期结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to examine mortality, health-related quality of life, and physical function among sepsis survivors who developed chronic critical illness.
DESIGN: Single-institution, prospective, longitudinal, observational cohort study assessing 12-month outcomes.
SETTING: Two surgical/trauma ICUs at an academic tertiary medical and level 1 trauma center.
PATIENTS: Adult critically ill patients that survived 14 days or longer after sepsis onset.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Baseline patient characteristics and function, sepsis severity, and clinical outcomes of the index hospitalization were collected. Follow-up physical function (short physical performance battery; Zubrod; hand grip strength) and health-related quality of life (EuroQol-5D-3L, Short Form-36) were measured at 3, 6, and 12 months. Hospital-free days and mortality were determined at 12 months. We compared differences in long-term outcomes between subjects who developed chronic critical illness (≥ 14 ICU days with persistent organ dysfunction) versus those with rapid recovery. The cohort consisted of 173 sepsis patients; 63 (36%) developed chronic critical illness and 110 (64%) exhibited rapid recovery. Baseline physical function and health-related quality of life did not differ between groups. Those who developed chronic critical illness had significantly fewer hospital-free days (196 ± 148 vs 321 ± 65; p < 0.0001) and reduced survival at 12-months compared with rapid recovery subjects (54% vs 92%; p < 0.0001). At 3- and 6-month follow-up, chronic critical illness patients had significantly lower physical function (3 mo: short physical performance battery, Zubrod, and hand grip; 6 mo: short physical performance battery, Zubrod) and health-related quality of life (3- and 6-mo: EuroQol-5D-3L) compared with patients who rapidly recovered. By 12-month follow-up, chronic critical illness patients had significantly lower physical function and health-related quality of life on all measures.
CONCLUSIONS: Surgical patients who develop chronic critical illness after sepsis exhibit high healthcare resource utilization and ultimately suffer dismal long-term clinical, functional, and health-related quality of life outcomes. Further understanding of the mechanisms driving the development and persistence of chronic critical illness will be necessary to improve long-term outcomes after sepsis.
参考来源
- Gardner AK, Ghita GL, Wang Z, et al. The Development of Chronic Critical Illness Determines Physical Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical ICUs. Crit Care Med. 2019. PMID: 30664526. doi:10.1097/CCM.0000000000003655
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。